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Running title: Impact of SAP on adverse outcomes after stroke 
 
Abstract 
Objectives: Stroke-Associated Pneumonia (SAP) is common and associated with adverse 
outcomes. Data on its impact beyond one year is scarce.  
Materials and methods: This observational study was conducted in a cohort of stroke 
patients admitted consecutively to a tertiary referral centre in the East of England, UK 
(January 2003 – April 2015). Logistic regression models examined in-patient mortality and 
length of stay (LOS). Cox-regression models examined longer term mortality at pre-defined 
time periods (0-90 days, 90 days-1 year, 1-3 years and 3-10 years) for SAP. Effect of SAP on 
functional outcome at discharge was assessed using logistic regression.                    
Results: A total of 9,238 patients [mean age (± SD) 77.61±11.88 years] were included. SAP 
was diagnosed in 1,083 (11.7%) patients. The majority of these cases (n=658; 60.8%) were 
aspiration pneumonia. After controlling for age, sex, stroke type, Oxfordshire Community 
Stroke Project classification (OCSP), pre-stroke modified Rankin scale, co-morbidities and 
acute illness markers, mortality estimates remained significant at three time periods; inpatient 
(OR 5.87, 95%CI [4.97-6.93]), 0-90 days (2.17[1.97-2.40]) and 91-365 days (HR 1.31[1.03-
1.67]). SAP was also associated with higher odds of long LOS (OR 1.93[1.67-2.22]) and 
worse functional outcome, (OR 7.17(5.44-9.45). In this cohort, SAP did not increase 
mortality risk beyond one year post stroke but it was associated with reduced mortality 
beyond 3 years. 
Conclusions: SAP is not associated with increased long term mortality but is linked with 
increased mortality up to 1 year, prolonged LOS, and poor functional outcome on discharge. 
Targeted intervention strategies are required to improve outcomes of SAP patients who 
survive to hospital discharge.   
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Introduction 
 
Pneumonia associated with stroke is common and often leads to poor clinical 
outcomes, with a recent systematic review reporting a prevalence of 14.3%.1 The 
pathophysiology of stroke-associated pneumonia (SAP) is multifactorial. Specifically, a 
combination of dysphagia leading to oro-pharyngeal aspiration and stroke-induced immuno-
suppression as a result of acute cerebral ischemia have been posited as possible mechanisms.2 
SAP may also consist of cases of pneumonia which precede the incident stroke thereby 
contributing to stroke etiopathogenesis.3 
Despite advances in organized stroke unit care over the last few decades,4 SAP 
continues to have negative impact on outcomes.5-10 SAP is independently associated with a 3-
fold increase in mortality during hospital admission,11 worse functional outcomes,9 longer 
length of hospitalization 5,7,10,12,13  and higher hospital costs.14 There is an extensive amount 
of research on the early outcome of SAP, however, it remains unclear whether or not the 
increased mortality risk persists after 1-year due to heterogeneity of these studies and lack of 
long-term follow up.2  
It is well-recognized that acute stroke induces both central nervous system (CNS) and 
peripheral inflammatory responses. Indeed, peripheral inflammatory markers are persistently 
elevated after stroke (to at least 3 months) compared to non-stroke controls, and are 
exacerbated by infectious complications.15,16 Peripheral inflammatory markers in the acute 
phase of stroke are associated with worse functional outcome, survival and recurrent vascular 
events in the interim and longer term.17 SAP, by augmenting acute and longer term 
inflammatory responses, complicating stroke might therefore plausibly contribute to longer 
term outcome after stroke.   
We hypothesized that SAP has adverse effects on longer-term outcomes compared to 
non-SAP. The main aim of this study therefore, was to investigate the association between 
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SAP and adverse outcomes including mortality at different pre-defined time periods; short 
(inpatient and 90 days), medium (91 days - 1 year) and long-term (1-3 years and 3-10 years). 
We also aimed to evaluate the effect of SAP on length of hospital stay and functional 
outcome at discharge. Our secondary aim was to explore the association between different 
types of SAP, namely aspiration and non-aspiration pneumonia based on clinicians’ diagnosis. 
 
Materials and methods 
Study participants and design 
Out of 11,886 entries on the stroke register, 9,238 patients with acute stroke who were 
admitted between 2003-2015 were included in the study. Supplementary Figure a-1 details 
the reasons for exclusion. Baseline demographic and clinical data of study participants were 
extracted from the comprehensive stroke and TIA register of a tertiary regional stroke center 
and ethical approval was granted by the Newcastle and Tyneside National Health Service 
(NHS) Research Ethics Committee (12/NE/0170).  
All acute stroke cases were verified by stroke physicians based on clinical features 
and CT/MRI imaging. SAP was defined as pneumonia diagnosed on admission or within the 
first seven days of admission after stroke onset.18 Information on the incidence of SAP 
(aspiration or non-aspiration) were retrieved from the hospital Patient Administration System 
(PAS), reviewed and identified with codes in the 10th revision of the International 
Classification of Disease (ICD-10), based on previously employed methods.19-22 The 
diagnosis of pneumonia was made by clinicians during the hospital stay based on signs and 
symptoms suggestive of acute lower respiratory tract infection based on British Thoracic 
Society (BTS) guidelines and previous studies.19 Further classification into aspiration and 
non-aspiration pneumonia was made by the clinician based on distinguishing features such as 
dysphagia status, nil by mouth and location of shadowing on chest X-ray, however the 
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accuracy may be limited by the lack of validated criteria for diagnosing aspiration 
pneumonia.22 The following diagnosis codes classified as SAP in the current study- J69; 
aspiration pneumonia and non-aspiration pneumonia including J12; Viral pneumonia, J13; 
Pneumonia due to Streptococcus pneumoniae, J14; due to Haemophilus-influenzae, J15; 
Bacterial, J16; Other infectious organisms, J17; pneumonia in diseases classified elsewhere 
and J18; unspecified organisms.  
 
Study outcomes 
The outcomes of interest were 1) Mortality - short term mortality (in-patient and 90 
days), medium (91 days – 1 year) and long term mortality (1-3 years and 3-10 years post-
stroke); 2) Long length of stay (LOS), defined as >14 days; 3) Functional outcome depicted 
by the modified Rankin Scale (mRS) score at discharge. The outcome was dichotomized as 
good (0-2) and poor (3-6).23 Linkage with the Office of National Statistics (ONS) for 
mortality data ensures near complete follow-up for this outcome. 
 
Potentially confounding covariates 
Data were collected on pre-existing co-morbidities. This information was retrieved 
from the hospital’s administration database. Co-morbid conditions examined in this study 
were stroke [ICDI60-64], transient ischaemic attack (TIA) [G45], coronary heart disease 
(CHD) [I20-25], myocardial infarction (MI) [I21], atrial fibrillation (AF) [I48], congestive 
heart failure (CHF) [I50], hypertension [I10-15], dyslipidaemia [E78], diabetes mellitus 
[E10-14], peripheral vascular disease (PVD) [I73.9], chronic obstructive pulmonary disease 
(COPD) [J40-44,J47], asthma [J45], previous pneumonia [J69, J12-18], chronic kidney 
disease (CKD) [N18], malignancy [C00-97], and dementia [F00-05]). Biochemical and 
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haematological measurements relevant to acute inflammatory response including total white 
cell count (WCC) and C-Reactive Protein (CRP) were collected on hospital admission. 
 
Statistical Analysis 
All analyses were agreed a-priori to avoid biased post-hoc decisions. We employed 
SPSS for Windows version 23.0 (SPSS Inc., Chicago, IL, USA). Chi-squared tests for 
categorical variables and Mann-Whitney U tests for continuous variables were used to 
compare the characteristics of those with and without SAP. Logistic regression models were 
constructed to examine in-patient mortality following SAP while Cox-regression models 
were used to examine longer term mortality outcomes (0-90 days, 91 days-1 year, 1-3 years 
and 3-10 years). Separate analyses were performed for each follow up period with subsequent 
models excluding patients for whom follow-up ended during the preceding period. This 
approach allowed us to consider the changing risk profile with older age after stroke. 
Analyses were conducted as follows: unadjusted (model A) and using five risk adjustment 
models that successively added covariates to control for age and sex (model B), stroke 
subtype (ischemic vs. hemorrhagic), OCSP classification, prior antiplatelet use (model C), 
co-morbidities (model D) and pre-stroke modified Rankin score (model E). Model F 
additionally controlled for WCC and CRP in a subgroup of patients where these parameters 
were available (n=7,425). Other stroke outcomes (long length of hospital stay and functional 
outcome) were assessed using binary logistic regression.  
The models were repeated to compare the outcomes in between aspiration (ICD J69) 
vs. non-aspiration pneumonia (ICD J12 – 18) based on their respective ICD codes using non-
aspiration pneumonia as the reference category and the fully-adjusted regression model as 
described. To investigate for any change in trend for mortality over the study period of 4263 
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days, survival following diagnosis of stroke according to pneumonia status and type of SAP 
were plotted and illustrated by the Kaplan-Meier survival curves.  
 
Results 
The prevalence of SAP was 11.7% (n=1,083). The mean age (SD) was 77.61 ± 11.88 
years, with 47.5% males, and 87.0% having had ischemic stroke. 77.1% cases of pneumonia 
were diagnosed on the same day as hospital admission and crude inpatient mortality was 
21.3% in those with SAP. Table 1 illustrates the baseline characteristics by pneumonia status 
and type.  Those with SAP were older, more likely to have a diagnosis of total anterior 
circulation stroke (TACS) and had a higher pre-stroke mRS. A significantly higher 
proportion of SAP patients had cardiovascular risk factors (hypertension and diabetes 
mellitus) and other co-morbid cardio-pulmonary conditions, dementia and malignancy.  
History of previous episode of pneumonia was significantly higher in patients who 
had SAP compared to those without SAP (15.1% vs 4.6%;p<0.001). In patients with SAP, 
60.8% were diagnosed with aspiration pneumonia. The age, severity of stroke depicted by 
OCSP and pre-stroke frailty depicted by pre-stroke mRS did not affect the prevalence of one 
type of pneumonia over the other. Patients with non-aspiration pneumonia were more likely 
to have COPD, CKD and higher median CRP [Median (IQR) 32(65.0) vs 23 (55.0)] mg/L on 
admission.  
Table 2 shows the mortality outcome during different time periods. The highest 
mortality following stroke was observed between 0 - 90 days while the risk of mortality was 
at its lowest after 3 years. The cumulative mortality was significantly greater for patients with 
SAP, particularly in those diagnosed with aspiration pneumonia. Supplementary Figure a-2 
and a-3 show KM cumulative survival by pneumonia status and type for the overall stroke 
cohort. The curve plateaus after approximately 1 year for those with SAP, indicating that the 
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excess/increased risk of mortality persists for 1 year in patients with SAP, after which SAP 
patients have a similar, then lower mortality rate to those without pneumonia beyond 3 years. 
Supplementary Figure a-4 shows that SAP conferred higher odds of inpatient and 0-90 days 
mortality in patients diagnosed with aspiration pneumonia (OR 1.54 and HR 1.29, 
respectively) compared to those diagnosed with non-aspiration pneumonia (p<0.005). They 
were also more likely to be associated with worse functional outcome (95.7% vs 88.7%, 
p<0.001) but the length of hospitalization was not significantly different. A log rank test for 
equality of survival functions showed a large difference between the different groups over 10 
years of follow up (p<0.001). 
Table 3 depicts the risk of mortality of SAP at various time intervals and the odds of 
prolonged LOS (>14 days) using non-pneumonia patients as reference. Patients with SAP 
had higher mortality rate compared with those without SAP at three time periods assessed 
(in-patient, 0-90 days and 91-365 days). SAP was associated with 5.87 times increased odds 
of in-patient mortality (95%CI 4.97 to 6.93), two times increased risk of 0-90 days mortality 
(HR 2.17 [95%CI 1.97 to 2.40]) and 31% increase in relative risk up to one year (95%CI: 
3%-67%). The risk of mortality remained consistently high up to 1 year despite further 
adjustments for WCC and CRP. However, it was noted that relative risk of mortality for SAP 
was halved (HR 0.50, 95%CI: 0.32-0.78) in those who survived beyond 3 years. We found a 
two-fold increase in the odds of long length of hospital stay in patients with SAP.  
The functional outcomes at discharge were available for 6,013 (65.1%) patients. Of 
those, 2,286 (38%) had good outcome (mRS 0-2) and 3,727 (62%) had poor outcome (mRS 
3-6). Patients with SAP had significantly worse functional outcomes at discharge (OR 7.17 
[95%CI 5.44-9.45]). Poor outcomes were observed in 885 (93%) of those with SAP (n=952) 
compared with 2,842 (56.2%) of those without (n=5,061) (Supplementary Figure a-5).  
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Discussion 
Our results confirm that SAP adversely affects mortality up to 1 year and is associated 
with prolonged hospitalization and poor functional status at discharge in patients after stroke, 
even after adjustment for various established prognostic factors. We further established that 
patients diagnosed with aspiration pneumonia have a higher short term mortality compared to 
patients diagnosed with non-aspiration pneumonia. 
SAP is arguably a preventable complication, which warrants increased efforts to 
identify those at risk and develop interventions to reduce incident cases given the impact of 
pneumonia on poor outcomes. To our knowledge, this is the first study analyzing the effect of 
SAP on mortality risk up to ten years of follow up. Existing literature either did not examine 
the mortality in specified time period or only took into account outcomes that developed 
early within 7 days to 3 months after stroke.7,9 Our long-term follow-up using consecutively 
admitted patient information enables us to provide novel insights into the longer-term 
prognosis of SAP. 
The overall frequency of SAP was 11.7%, corroborating results observed in previous 
studies.9,21,24 Patients with SAP were older, more likely to have a diagnosis of TACS, had a 
higher pre-stroke mRS and had more additional co-morbidities, and higher inflammatory 
markers.  These findings, in line with previous studies,5,11,12 suggest that patients with SAP 
have a higher severity of disease, medical complexity and frailty. We found that 77.1% of 
patients with SAP were diagnosed on the day of admission. This figure is higher than that 
reported in the literatures, i.e 40-68%.6,21,25 This discrepancy may be explained by marked 
heterogeneity between studies, influenced by factors such as study population, environment 
and approach to diagnosis.1 Our higher rate of pickup may also be due to the presence of a 
hyperacute bay with constant physiological monitoring which may benefit from more 
rigorous detection of infection. However, the early diagnosis of SAP in our study did not 
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translate into better outcomes which may be explained by the lack of efficacy of prophylactic 
antibiotics given within 24 and 48 hours of stroke onset as shown in two recent trials.26,27 It 
has been proposed that administration of preventative antibiotics in these trials may in fact 
have been too late to prevent SAP and that the results are limited by the heterogeneity of 
antibiotics choice.28 This necessitates a paradigm shift to initiate preventative interventions, 
for those at risk of SAP, in the hyperacute phase (under 24 hours) of stroke in future large 
clinical trials. 
There is substantial variation in terms of the reported mortality rate across different 
studies.5,6,8,12,13,29 The overall mortality rates in this study were slightly higher than previous 
studies, with 61.5% at discharge and 73.6% at 1 year (Table 2). Notably, we observed excess 
mortality from SAP even among those surviving up to one year following hospitalization. 
This was accompanied by a plateau and reduction in mortality risk after 3 years. Although 
this observation has not been previously described, several mechanisms have been proposed 
to explain this effect. This finding could be influenced by the small number of patients with 
SAP who survived beyond 3 years. Alternatively, we may be limited by residual confounding. 
Despite robust covariate adjustments in our study, it is possible that better prognosis after 
three years in participants with SAP could be attributable to other factors that were not 
accounted for in our analyses, such as newly developing chronic co-morbid disease impacting 
on mortality. Whilst the overall sample size is reasonable between 3-10 years (n=5,223), only 
208 patients with SAP have survived up to 3 years suggesting that most who will die as a 
result of SAP would have died within the first 3 years after stroke. This may also be because 
of the significantly higher age of patients with SAP, resulting in earlier death (before 3 years) 
due to age-related factors compared to patients without SAP. Furthermore, it is also possible 
that the severity of SAP they had was mild leading to lower risk in later time periods. It is 
probable that non-SAP group is catching up with mortality as those who survived beyond 
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three years have higher co-morbid burden with time and associated increased frailty which 
were not accounted for in the analysis.  
One study used survival analyses to examine the long term impact of the medical 
complications in stroke patients beyond 1 year.24 It was shown that cumulative mortality 
continued to rise over the entire follow up period (4 years), never reaching a plateau. The 
authors highlighted that the excess risk of death following medical complication never abated, 
suggesting that the characteristics of the population were responsible rather than the insults of 
the complication episode. The findings of the present study are an initial observation and 
whether this represents the true impact of SAP on long term outcomes needs to be further 
tested in different populations.  
Traditionally, SAP has been thought to be aspiration related secondary to dysphagia. 
However, recent studies have shown that up to half of patients that develop pneumonia post 
stroke do not aspirate which implies that not all SAP is aspiration-related.6 In line with 
published literature, 20,30 we observed differences in the characteristics and outcomes between 
the diagnoses of aspiration and non-aspiration pneumonia. Those diagnosed with aspiration 
pneumonia were more likely to have higher short term mortality and poor functional outcome 
compared to those with non-aspiration pneumonia. Patients with aspiration pneumonia had a 
significantly higher proportion of TACS compared to non-aspiration pneumonia when tested 
for statistical significance individually and this may reflect higher severity of disease in those 
diagnosed with aspiration pneumonia. We controlled for stroke type, stroke severity and a 
wide range of confounding factors in our multivariable analyses. Therefore, outcomes are 
likely due to the type of pneumonia. Although we acknowledge that we were limited by the 
lack of dysphagia status in patients. For stroke patients truly experiencing aspiration, the 
pathophysiological basis for poorer outcomes can be explained by the presence of 
oropharyngeal or gastric contents in the airway which can result in a higher severity of 
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epithelial disruption, impaired gas exchange and prolonged healing than when the airway is 
exposed to exogenous bacteria alone.31,32 
However, the accuracy of categorizing aspiration and non-aspiration pneumonia by 
hospital clinicians is not within the scope of this study and the retrospective nature of this 
study does not allow verification of the accuracy of the type of pneumonia diagnosis. The 
difficulties in studying aspiration pneumonia is well recognized throughout the literature due 
to the lack of a sensitive and specific marker for aspiration pneumonia, as well as the 
potential overlap of clinical signs and symptoms between aspiration pneumonia and other 
forms of pneumonia.33 Although we categorized SAP into aspiration vs non-aspiration 
subtypes based on available clinical and investigation data for the analyses, we acknowledge 
that accurately discriminating these subtypes in clinical practice is challenging and the 
prognostic value is uncertain. 
Our study has several strengths. The nature of our study with a long follow-up period 
enabled us to provide more robust prognostic information on the long-term impact of SAP.  
This study is also unique in having a large and well-defined stroke population that is 
representative of real-world stroke population, all of whom had relevant measurements of 
disease at baseline and were followed prospectively until death or the end of study period. 
The availability of these information allowed us to adjust for many potential confounders in 
our analysis including inflammatory markers which are important determinants of stroke 
outcome.15 
Our study has several limitations in addition to those described earlier. The clinical 
severity of pneumonia was not accounted for in this study and misclassification of pneumonia 
type is a possibility due to lack of a “gold standard” for the diagnosis of aspiration 
pneumonia. We had to rely on the clinician’s best judgment to determine if the mechanism of 
pneumonia was aspiration or non-aspiration and this carries a margin of error.34 However, the 
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data came from a single unit with yearly patient flow of approximately 1,000 per annum 
stroke cases looked after by a single stroke team with 3-5 consultants during the study period. 
The shift system within the NHS suggests that most patients were looked after by more than 
one consultant in each hospital episode and hence any disagreement in diagnosis would have 
been resolved with final coding verified. The discharge mRS were only available in 65.1% of 
the population, which could have led to underestimation of the functional outcome. 
Nevertheless, the internal relationship between SAP and outcome is unlikely to be different.  
Finally, data to assess the severity of stroke impairment such as the National Institute of 
Health Stroke Scale (NIHSS) were not available. However, we adjusted for OCSP 
classification and pre-stroke mRS, which has been shown to be indicative of major 
determinants of mortality in stroke.35  
We found that SAP was not associated with poorer long term outcomes. However, our 
findings that SAP is significantly associated with higher mortality up to 1 year, longer 
hospitalization and worse functional outcome highlight the importance of early identification 
and treatment of SAP. Future efforts should aim to develop better ways of identifying stroke 
patients at high risk for aspiration and pneumonia and on strategies to prevent this 
complication. 
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Table 1. Characteristics of stroke patients at admission by pneumonia status and type 
Characteristics  Stroke-Associated Pneumonia 
 Total  
n= 9238 
Yes  
n= 1083 (11.7) 
No  
n= 8155 (88.3) 
P-Value Aspiration  
n=658 (60.8) 
Non-aspiration  
n=425(39.2)  
P-Value 
Age,    <0.001   0.759 
65 and below 1404 (15.2) 51 (4.7) 1353 (16.6)  29 (4.4) 22 (5.2)  
66-75 1868 (20.2) 158 (14.6) 1710 (21.0)  97 (14.7) 61 (14.4)  
76-85 3481 (37.7) 451 (41.6) 3030 (37.2)  268 (40.7) 183 (43.1)  
86 and above 2485 (26.9) 423 (39.1) 2062 (25.3)  264 (40.1) 159 (37.4)  
Sex    0.402   0.882 
Female 4853 (52.5) 556 (51.3) 4297 (52.7)  339 (51.5) 217 (51.1)  
Male 4385 (47.5) 527 (48.7) 3858 (47.3)  319 (48.5) 208 (48.9)  
OCSP Classification    <0.001   0.759 
LACS 2134 (23.1) 113 (10.4) 2021 (24.8)  57 (8.7) 56 (13.2)  
PACS 3117 (33.7) 308 (28.4) 2809 (34.4)  174 (26.4) 134 (31.5)  
POCS 1581 (17.1) 142 (13.1) 1439 (17.6)  88 (13.4) 54 (12.7)  
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TACS 1877 (20.3) 462 (42.7) 1415 (17.4)  303 (46.0) 159 (37.4)  
Unspecified 529 (5.7) 58 (5.4) 471 (5.8)  36 (5.5) 22 (5.2)  
Pre-Stroke Modified 
Rankin Score 
   <0.001   0.248 
0 5849 (63.3) 529 (48.8) 5320 (65.2)  335 (50.9) 194 (45.6)  
1 1100 (11.9) 149 (13.8) 951 (11.7)  84 (12.8) 65 (15.3)  
2 757 (8.2) 116 (10.7) 641 (7.9)  64 (9.7) 52 (12.2)  
3 883 (9.6) 154 (14.2) 729 (8.9)  95 (14.4) 59 (13.9)  
4 451 (4.9) 96 (8.9) 355 (4.4)  53 (8.1) 43 (10.1)  
5 198 (2.1) 39 (19.7) 159 (1.9)  27 (4.1) 12 (2.8)  
Type of Stroke    0.939   0.065 
Ischemic 8037 (87.0) 943 (87.1) 7094 (87.0)  563 (85.6) 380 (89.4)  
Hemorrhagic 1201 (13.0) 140 (12.9) 1061 (13.0)  95 (14.4) 45 (10.6)  
Admission Antithrombotic    0.073   0.633 
Yes 4745 (51.4) 584 (53.9) 4161 (51.0)  307 (46.7) 192 (45.2)  
No 4493 (48.6) 499 (46.1) 3994 (49.0)  351 (53.3) 233 (54.8)  
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Co-morbidities        
Stroke/TIA 1099 (11.9) 147 (13.6) 952 (11.7) 0.070 84 (12.8) 63 (14.8) 0.334 
CHD/MI 1625 (17.6) 265 (24.5) 1360 (16.7) <0.001 162 (24.6) 103 (24.2) 0.886 
AF 2239 (24.2) 400 (36.9) 1839 (22.6) <0.001 239 (36.3 ) 161 (37.9) 0.603 
CHF 996 (10.8) 199 (18.4) 797 (9.8) <0.001 119 (18.1) 80 (18.8) 0.759 
Hypertension 4354 (47.1) 550 (50.8) 3804 (46.6) 0.010 334 (50.8) 216 (50.8) 0.984 
Dyslipidemia 863 (9.3) 72 (6.6) 791 (9.7) 0.001 44 (6.7) 28 (6.6) 0.949 
Diabetes Mellitus 1243 (13.5) 178 (16.4) 1065 (13.1) 0.002 108 (16.4) 70 (16.5) 0.980 
PVD 283 (3.1) 36 (3.3) 247 (3.0) 0.596 20 (3.0) 16 (3.8) 0.516 
COPD 541 (5.9) 101 (9.3) 440 (5.4) <0.001 52 (7.9) 49 (11.5) 0.045 
Asthma 664 (7.2) 87 (8.0) 577 (7.1) 0.252 51 (7.8) 36 (8.5) 0.670 
History of pneumonia  537 (5.8) 164 (15.1) 373 (4.6) <0.001 89 (13.5) 75 (17.6) 0.065 
CKD 380 (4.1) 62 (5.7) 318 (3.9) 0.004 25 (3.8) 37 (8.7) 0.001 
Malignancy 1112 (12.0) 155 (14.3) 957 (11.7) 0.014 87 (13.2) 68 (16.0) 0.202 
Dementia 316 (3.4) 64 (5.9) 252 (3.1) <0.001 40 (6.1) 24 (5.6) 0.768 
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WCC, x 109/L 9.1 (4.4)* 10.30 (5.5)* 9.00 (4.2)* <0.001 10.10 (5.6)** 10.45 (5.5)** 0.281 
CRP, mg/L 12.00 (33)* 26.00 (60)* 11.00 (28)* <0.001 23.00 (55.0)** 32.00 (65.0)** 0.010 
 
Categorical data are presented as frequency counts (%) and continuous data such as WCC and CRP are presented as median (IQR).  
* Subgroup analysis, n=7425, a total of 1813 cases were not included in the analysis of WCC and CRP due to missing data. 
**Subgroup analysis, n=1023, a total of 60 cases were not included in the analysis due to missing WCC and CRP 
Abbreviation: Oxfordshire Community Stroke Project (OCSP) classification, Lacunar stroke (LACS), Partial Anterior Circulation Stroke 
(PACS), Posterior Circulation Stroke (POCS), Total Anterior Circulation Stroke (TACS), Transient Ischemic Attack (TIA), Coronary Heart 
Disease (CHD)/ Myocardial Infarction (MI), Atrial Fibrillation (AF), Congestive Heart Failure (CHF), Peripheral Vascular Disease (PVD), 
Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Disease (CKD. 
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Table 2. Mortality of patients at different time periods 
 
Time 
periods 
No stroke-associated pneumonia Stroke-associated pneumonia Aspiration pneumonia Non-aspiration pneumonia 
No. 
at 
risk 
No. 
deaths 
(%) 
Risk of 
mortality 
(chance in 
1000)/wk 
Cumulative 
mortality 
function(%
) (95%CI) 
No. 
at 
risk 
No. 
deaths 
(%) 
Risk of 
mortality 
(chance 
in 1000)/ 
wk 
Cumulative 
mortality 
function(%) 
(95%CI) 
No. 
at 
risk 
No. 
deaths 
(%) 
Risk of 
mortality 
(chance 
in 1000)/ 
wk 
Cumulative 
mortality 
function(%) 
(95%CI) 
No. 
at 
risk 
No. 
deaths 
(%) 
Risk of 
mortality 
(chance 
in 1000)/ 
wk 
Cumulative 
mortality 
function(%) 
(95%CI) 
In-patient  8155 1305 
(16.0) 
- 16.0 
(15.3-16.8) 
1083 666 
(61.5) 
- 61.5  
(58.6-64.4) 
658 433 
(65.8) 
- 65.8  
(62.2-69.4) 
425 233 
(54.8) 
- 54.8  
(62.2-69.4) 
0-90 Days  8155 1761 
(21.6) 
16.6 21.6  
(20.7-22.5) 
1083 714 
(65.9) 
50.7 65.9  
(63.1-68.7) 
658 458 
(69.6) 
53.5 69.6  
(66.1-73.1) 
425 256 
(60.2) 
46.3 60.2  
(55.6-64.9) 
91-365 
Days  
6394 678 
(10.6) 
2.7 29.9 
(28.9-30.9) 
369 83 
(22.5) 
5.7 73.6  
(71.0-76.2) 
200 49 
(24.5) 
6.2 77.1 
(73.9-80.3) 
169 34 
(20.1) 
5.1 68.2  
(63.8-72.6) 
366-1095 
Days 
5716 723 
(12.6) 
1.2 38.8  
(37.7-39.9) 
286 56 
(19.6) 
1.9 78.8  
(76.4-81.2) 
151 28 
(18.5) 
1.8 81.3  
(78.3-84.3) 
135 28 
(20.7) 
2.0 74.8  
(70.7-78.9) 
1096-
3650 
Days 
4993 775 
(15.5) 
0.4 48.3  
(47.2-49.4) 
230 22 
(9.6) 
0.3 80.8  
(78.5-83.2) 
123 12 
(9.8) 
0.3 83.1  
(80.2-86.0) 
107 10 
(9.3) 
0.3 77.2  
(73.2-81.2) 
 
 25 
Table 3. Odds /Hazards ratio with corresponding 95% confidence intervals at different time periods for mortality outcomes and long length of 
hospital stay for patients with SAP compared to those without that were admitted to the regional stroke unit (2003 to 2015) in Norfolk, England, 
UK. 
 
Model Mortality† Odds of Long Length of 
Stay (>14 days) † In-patient Mortality 
(OR)  
0-90 Days (HR)  91- 365 Days (HR)  366-1095 Days (HR) 1096- 3650 Days 
(HR) 
A 8.38 (7.32-9.60) *** 4.08 (3.73-4.45) *** 2.28 (1.81-2.86) *** 1.63 (1.24-2.14) *** 0.62 (0.41-0.95)* 2.76 (2.43-3.14) *** 
B 7.60 (6.60-8.74) *** 3.50 (3.21-3.83) *** 1.91 (1.52-2.40) *** 1.38 (1.05-1.82) * 0.54 (0.35-0.82)** 2.48 (2.17-2.82) *** 
C 7.04 (6.02-8.24) *** 2.53 (2.31-2.77) *** 1.73 (1.37-2.18) *** 1.39 (1.06-1.83) * 0.56 (0.37-0.86)** 2.22 (1.94-2.54) *** 
D 6.75 (5.75-7.92) *** 2.36 (2.15-2.60) *** 1.58 (1.25-2.00) *** 1.34 (1.01-1.76) * 0.58 (0.37-0.88)* 2.23 (1.94-2.55) *** 
E 6.56 (5.58-7.70) *** 2.29 (2.09-2.52) *** 1.51 (1.19-1.92) ** 1.21 (0.92-1.60) 0.59 (0.38-0.91)* 2.17 (1.89-2.48) *** 
F 5.87 (4.97-6.93) *** 2.17 (1.97-2.40) *** 1.31 (1.03-1.67) * 1.11 (0.83-1.47) 0.50 (0.32-0.78)** 1.93 (1.67-2.22) *** 
 
P-value*<0.05, **<0.01, ***<0.001 
Model A= Unadjusted 
Model B= Adjusted for age and sex 
Model C= Adjusted for model B + stroke type, Oxfordshire Community Stroke Project Classification, and prior antiplatelet use 
Model D= Adjusted for model C + and co-morbidities†† 
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Model E= Adjusted for model E + pre-stroke modified Rankin score 
Model F= Adjusted for model E + WCC and CRP. Subgroup analysis, n = 7425 
†The in-patient mortality and odds of long length of stay are derived from binary logistic regression models. The 90-, 365- and 1095-days 
mortality hazard ratios are analyzed by Cox regression models. Long length of stay is defined as hospital stay of more than 14 days since the day 
of admission. 
††Co-morbidities adjusted include Previous Stroke/TIA, MI/CHD, AF, CHF, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral 
Vascular Disease, COPD, Asthma, Pneumonia before admission, CKD, Malignancy, Dementia 
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Supplementary Figure a-1: Patient inclusion criteria  
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Supplementary Figure a-2: Survival following diagnosis of stroke according to pneumonia status (Kaplan-Meier survival curve), n=9238; Log 
rank test, p<0.001. 
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Supplementary Figure a-3: Survival following diagnosis of stroke according to subtypes of stroke-associated pneumonia; either aspiration or 
non-aspiration pneumonia (Kaplan-Meier survival Curve), n=1083; Log rank test, p<0.001. 
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Supplementary Figure a-4: Risk estimates of outcome for aspiration pneumonia vs non-aspiration pneumonia (with non-aspiration pneumonia as 
the reference category) 
 
 
 
P*<0.05, **<0.01, ***<0.001 
Binary logistic models were used in the analysis of in-patient mortality and long length of stay. Cox-regression models were used to analyze the 
90-, 365-, 1095- and 3650- Days mortality.  
All Binary Logistic Models and Cox-regression Models were Adjusted For:  Age, Sex, Stroke Type, Oxfordshire Community Stroke Project 
Classification, Pre-stroke modified Rankin score, Prior Antiplatelet Use, Co-Morbidities (Previous Stroke/Transient Ischemic Attack, 
Myocardial Infarction/Coronary Heart Disease, Congestive Heart Failure, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral Vascular 
Disease, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Falls, Malignancy, Dementia)  
 
Aspiration  
Non-Aspiration 
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Supplementary Figure a-5: Functional outcome at discharge of all stroke patients (n=6013) and those of the subgroups stratified according to 
pneumonia status ( SAP vs non-SAP) and pneumonia type (aspiration vs non-aspiration)  
  
 
Modified rankin score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional outcomes at discharge were available in 65% of patients. Binary logistic regression analysis was performed in 65% (n=6013) patients 
who had available discharge mRS and p value was obtained. SAP was associated with a poor outcome at discharge, OR 7.17 (95%CI 5.44-9.45), 
p<0.001. Good outcome was defined as mRS 0-2 and poor outcome was defined as 3-6. 
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